AbbVie Inc. $ABBV Shares Sold by Cliftonlarsonallen Wealth Advisors LLC

Cliftonlarsonallen Wealth Advisors LLC cut its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 12.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 22,012 shares of the company’s stock after selling 3,148 shares during the quarter. Cliftonlarsonallen Wealth Advisors LLC’s holdings in AbbVie were worth $5,030,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Evolution Wealth Management Inc. acquired a new stake in AbbVie during the 2nd quarter worth approximately $26,000. Chelsea Counsel Co. acquired a new stake in AbbVie during the 3rd quarter worth approximately $26,000. Westend Capital Management LLC acquired a new stake in AbbVie during the 4th quarter worth approximately $29,000. Texas Capital Bancshares Inc TX acquired a new stake in AbbVie during the 3rd quarter worth approximately $31,000. Finally, Caitlin John LLC acquired a new stake in AbbVie during the 3rd quarter worth approximately $33,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie filed a lawsuit seeking clearer, narrower guidance on which patients qualify for a federal drug discount program — a step that could limit discount exposure and protect revenue/margins if the court or settlement tightens eligibility. AbbVie files lawsuit to address ‘outdated’ drug discount eligibility program
• Positive Sentiment: New dermatology data showcased at the AAD meeting (Skyrizi and Rinvoq long‑term outcomes, safety and expanded labels) support AbbVie’s immunology growth thesis and help de‑risk revenue concentration away from Humira. Can AbbVie’s (ABBV) New Dermatology Data Quietly Reshape Its Immunology-Heavy Investment Story?
• Positive Sentiment: Analyst support and dividend/cash‑flow strength: recent analyst notes (including high price targets from JPMorgan and an overweight stance from Cantor Fitzgerald despite a modest PT trim) plus strong free cash flow and a reliable dividend underpin investor confidence. AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns Cantor Fitzgerald lowers price target to $240, remains Overweight
• Neutral Sentiment: Broader health-care sector strength lifted stocks broadly today, providing a tailwind to ABBV alongside company‑specific news. Sector Update: Health Care Stocks Advance in Afternoon Trading
• Neutral Sentiment: Market commentary and trending coverage (Zacks, Seeking Alpha) are spotlighting AbbVie’s pipeline and dividend, keeping the name on investor radars but not adding new hard catalysts. AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
• Negative Sentiment: AbbVie added Humira to the TrumpRx program at a steep (reported ~86%) discount for broader access — a move that could pressure Humira residual revenues and overall pricing power in the U.S. over time. Humira’s TrumpRx Discount Raises New Questions For AbbVie Valuation
• Negative Sentiment: Valuation and guidance risks remain: some analysts and commentators flag that recent volatility, competitive pressures and any guidance softness could limit upside despite strong drug growth — a caution that can weigh on the stock if sentiment flips. Why The AbbVie (ABBV) Story Is Shifting As Immunology Hopes Meet Valuation Doubts

Insider Buying and Selling at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.25% of the stock is owned by company insiders.

AbbVie Trading Up 2.6%

Shares of ABBV opened at $211.74 on Thursday. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The firm’s fifty day simple moving average is $220.80 and its 200-day simple moving average is $224.19. The firm has a market capitalization of $374.40 billion, a price-to-earnings ratio of 89.72, a PEG ratio of 0.73 and a beta of 0.38.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same period last year, the business earned $2.16 EPS. The company’s revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.3%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. BMO Capital Markets reiterated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Barclays assumed coverage on shares of AbbVie in a report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price objective on the stock. Guggenheim restated a “buy” rating on shares of AbbVie in a report on Thursday, March 12th. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and raised their price objective for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. Finally, Berenberg Bank set a $275.00 price objective on shares of AbbVie in a report on Tuesday, January 20th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $252.65.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.